Investors

The company is developing two late stage and complementary assets to target unmet medical and societal needs and have significant commercial potential.

Our highly experienced team have between them led the development, launch and successful commercialisation of radiopharmaceuticals, x-ray and MR contrast media as well as nuclear medicine, ultrasound, MR and CT scanners for the industry’s leading global players.

If you would like to learn more please contact:

David Hail, CEO Serac Life Sciences